Follow the people · Insider
David Kirn
David Kirn files insider transactions with the SEC as a director and officer of 4D Molecular Therapeutics (FDMT). We hold 7 disclosed purchases and sales filed since 10 March 2021, 6 of them in the last 90 days.
- Files forFDMT
- Disclosed buys and sells7 in all, 6 in the last 90 days
- Last disclosure21 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 8 March 2021 — 19 August 2026Director and Officer · 4D Molecular Therapeutics (FDMT)44 Form 4 lines · source: SEC Form 4
Everything they disclosed
44 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 50,000 shares of 4D Molecular TherapeuticsSEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 43,149 shares of 4D Molecular TherapeuticsSEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 25,927 shares of 4D Molecular TherapeuticsSEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- exercised options over 50,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 421 August 2026Stock Option (Right to Buy) · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 26,842 shares of 4D Molecular TherapeuticsSEC Form 45 August 2026Common Stock · traded 4 August 2026 · filed 5 August 2026
- ▼ sold on the open market 12,415 shares of 4D Molecular TherapeuticsSEC Form 44 August 2026Common Stock · traded 3 August 2026 · filed 4 August 2026
- ▼ sold on the open market 42,608 shares of 4D Molecular TherapeuticsSEC Form 414 July 2026Common Stock · traded 9 July 2026 · filed 14 July 2026
- ▼ sold on the open market 15,283 shares of 4D Molecular TherapeuticsSEC Form 414 July 2026Common Stock · traded 10 July 2026 · filed 14 July 2026
- ▼ sold on the open market 442 shares of 4D Molecular TherapeuticsSEC Form 414 July 2026Common Stock · traded 10 July 2026 · filed 14 July 2026
- ▼ sold on the open market 114,746 shares of 4D Molecular TherapeuticsSEC Form 423 June 2026Common Stock · traded 22 June 2026 · filed 23 June 2026
- ▼ sold on the open market 1,922 shares of 4D Molecular TherapeuticsSEC Form 42 June 2026Common Stock · traded 1 June 2026 · filed 2 June 2026
- was granted 750,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 427 March 2026Stock Option (Right to Buy) · traded 25 March 2026 · filed 27 March 2026
- was granted 750,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 427 March 2026Stock Option (Right to Buy) · traded 25 March 2026 · filed 27 March 2026
- was granted 267,500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 410 March 2025Stock Option (Right to Buy) · traded 6 March 2025 · filed 10 March 2025
- exercised options over 11,653 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 July 2024Stock Option (Right To Buy) · traded 10 July 2024 · filed 12 July 2024
- exercised options over 1,270 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 July 2024Stock Option (Right To Buy) · traded 10 July 2024 · filed 12 July 2024
- exercised options over 11,653 shares of 4D Molecular TherapeuticsSEC Form 412 July 2024Common Stock · traded 10 July 2024 · filed 12 July 2024
- exercised options over 1,270 shares of 4D Molecular TherapeuticsSEC Form 412 July 2024Common Stock · traded 10 July 2024 · filed 12 July 2024
- ▼ sold on the open market 12,923 shares of 4D Molecular TherapeuticsSEC Form 412 July 2024Common Stock · traded 10 July 2024 · filed 12 July 2024
- exercised options over 12,930 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 426 June 2024Stock Option (Right To Buy) · traded 24 June 2024 · filed 26 June 2024
- exercised options over 12,930 shares of 4D Molecular TherapeuticsSEC Form 426 June 2024Common Stock · traded 24 June 2024 · filed 26 June 2024
- ▼ sold on the open market 12,930 shares of 4D Molecular TherapeuticsSEC Form 426 June 2024Common Stock · traded 24 June 2024 · filed 26 June 2024
- ▼ sold on the open market 92,001 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 5,696 shares of 4D Molecular TherapeuticsSEC Form 425 January 2024Common Stock · traded 23 January 2024 · filed 25 January 2024
- ▼ sold on the open market 28,632 shares of 4D Molecular TherapeuticsSEC Form 48 January 2024Common Stock · traded 15 December 2023 · filed 8 January 2024
- ▼ sold on the open market 4,702 shares of 4D Molecular TherapeuticsSEC Form 48 January 2024Common Stock · traded 18 December 2023 · filed 8 January 2024
- ▼ sold on the open market 40,732 shares of 4D Molecular TherapeuticsSEC Form 48 January 2024Common Stock · traded 4 January 2024 · filed 8 January 2024
- ▼ sold on the open market 28,104 shares of 4D Molecular TherapeuticsSEC Form 48 January 2024Common Stock · traded 5 January 2024 · filed 8 January 2024
- ▼ sold on the open market 133 shares of 4D Molecular TherapeuticsSEC Form 48 January 2024Common Stock · traded 5 January 2024 · filed 8 January 2024
- was granted 590,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 413 December 2023Stock Option (Right to Buy) · traded 11 December 2023 · filed 13 December 2023
- gave away 600,000 shares of 4D Molecular TherapeuticsSEC Form 44 May 2023Common Stock · traded 2 May 2023 · filed 4 May 2023
- gave away 600,000 shares of 4D Molecular TherapeuticsSEC Form 44 May 2023Common Stock · traded 2 May 2023 · filed 4 May 2023
- ▼ sold on the open market 17,090 shares of 4D Molecular TherapeuticsSEC Form 423 February 2023Common Stock · traded 21 February 2023 · filed 23 February 2023
- ▼ sold on the open market 907 shares of 4D Molecular TherapeuticsSEC Form 423 February 2023Common Stock · traded 21 February 2023 · filed 23 February 2023
- ▼ sold on the open market 16,449 shares of 4D Molecular TherapeuticsSEC Form 423 February 2023Common Stock · traded 22 February 2023 · filed 23 February 2023
- was granted 222,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 414 February 2023Stock Option (Right to Buy) · traded 10 February 2023 · filed 14 February 2023
- ▼ sold on the open market 10,899 shares of 4D Molecular TherapeuticsSEC Form 423 January 2023Common Stock · traded 19 January 2023 · filed 23 January 2023
- ▼ sold on the open market 8,625 shares of 4D Molecular TherapeuticsSEC Form 423 January 2023Common Stock · traded 20 January 2023 · filed 23 January 2023
- ▼ sold on the open market 31,433 shares of 4D Molecular TherapeuticsSEC Form 419 December 2022Common Stock · traded 15 December 2022 · filed 19 December 2022
- ▼ sold on the open market 1,500 shares of 4D Molecular TherapeuticsSEC Form 419 December 2022Common Stock · traded 15 December 2022 · filed 19 December 2022
- ▼ sold on the open market 27,595 shares of 4D Molecular TherapeuticsSEC Form 419 December 2022Common Stock · traded 16 December 2022 · filed 19 December 2022
- ▼ sold on the open market 26,349 shares of 4D Molecular TherapeuticsSEC Form 419 December 2022Common Stock · traded 16 December 2022 · filed 19 December 2022
- was granted 150,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 February 2022Stock Option (Right to Buy) · traded 1 February 2022 · filed 3 February 2022
- was granted 150,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 410 March 2021Stock Option (Right to Buy) · traded 8 March 2021 · filed 10 March 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.